Data / Form D filings / Satellos Bioscience Inc.
Satellos Bioscience Inc.: Form D filings
Satellos Bioscience Inc., a biotechnology company in Toronto, Ontario, Canada, filed 10 Form D notices with the SEC between 2009 and 2025. The latest, on January 3, 2025, reports $25 million sold of a $25 million offering to 13 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- ROYAL BANK PLAZA, S. TOWER, 200 BAY ST., SUITE 2800, Toronto, Ontario, Canada, M5J 2
- Phone
- (416) 708-0522
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Canada (Federal Level)
- Year incorporated
- 2021
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1421642
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Jan 3, 2025 | New notice | $25,016,264 | $25,016,264 | 13 | Dec 20, 2024 | sec.gov | |
| May 25, 2023 | New notice | $33,292,573 | $33,292,573 | 16 | May 10, 2023 | sec.gov | |
| Sep 27, 2022 | New notice | $2,101,450 | $99,161 | $2,002,289 | 1 | Sep 13, 2022 | sec.gov |
| Sep 10, 2019 | New notice | $2,511,657 | $187,999 | $2,323,658 | 1 | Aug 19, 2019 | sec.gov |
| Mar 8, 2019 | New notice | $971,685 | $151,826 | $819,859 | 1 | Feb 22, 2019 | sec.gov |
| Feb 5, 2014 | New notice | $7,930,682 | $2,027,393 | $5,903,289 | 2 | Jan 27, 2014 | sec.gov |
| Nov 21, 2013 | Amendment | $125,914 | $125,914 | 1 | Nov 2, 2011 | sec.gov | |
| Nov 15, 2011 | New notice | $50,367 | $50,367 | 1 | Nov 2, 2011 | sec.gov | |
| Dec 1, 2009 | Amendment | $3,303,118 | $3,303,118 | 5 | Oct 29, 2009 | sec.gov | |
| Nov 6, 2009 | New notice | $2,706,195 | $2,706,195 | 2 | Oct 29, 2009 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Franklin D. Berger | Director | |
| Frank Gleeson | Executive Officer, Director, Promoter | |
| Michael Robert Cross | Executive Officer | |
| William McVicar | Director | |
| Brian Bloom | Director | |
| Elizabeth Williams | Executive Officer | |
| Stephanie D. Brown | Director | |
| Michael Rudnicki | Executive Officer | |
| Bill Jarosz | Director | |
| Adam Mostafa | Director | |
| Philip D. Lambert | Executive Officer | |
| Courtney D. Wells | Executive Officer | |
| Geoff MacKay | Director | |
| Rima Al-awar | Director |
Every Form D from the week of Dec 30, 2024 · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Satellos Bioscience Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.